Zürcher Nachrichten - Asia-Pacific gets new weapon in fight against drug-resistant TB

EUR -
AED 4.02547
AFN 78.958383
ALL 99.102869
AMD 431.181955
ANG 1.961978
AOA 1003.890567
ARS 1184.765046
AUD 1.813586
AWG 1.97271
AZN 1.867466
BAM 1.955265
BBD 2.22659
BDT 133.983319
BGN 1.957778
BHD 0.412787
BIF 3277.602688
BMD 1.09595
BND 1.474296
BOB 7.619914
BRL 6.405394
BSD 1.102698
BTN 94.079244
BWP 15.358795
BYN 3.608812
BYR 21480.619234
BZD 2.215094
CAD 1.559263
CDF 3148.664634
CHF 0.944431
CLF 0.02729
CLP 1047.223301
CNY 7.980215
CNH 7.994999
COP 4582.945323
CRC 557.847278
CUC 1.09595
CUP 29.042674
CVE 110.234821
CZK 25.256829
DJF 196.376238
DKK 7.461451
DOP 69.640934
DZD 146.03502
EGP 55.406831
ERN 16.439249
ETB 145.347308
FJD 2.537019
FKP 0.848847
GBP 0.850992
GEL 3.01429
GGP 0.848847
GHS 16.936386
GIP 0.848847
GMD 78.318573
GNF 9501.669172
GTQ 8.456513
GYD 230.334669
HKD 8.520633
HNL 28.123814
HRK 7.531044
HTG 145.64165
HUF 405.948886
IDR 18161.758515
ILS 4.100568
IMP 0.848847
INR 93.716415
IQD 1435.708041
IRR 46033.956886
ISK 144.87989
JEP 0.848847
JMD 172.346268
JOD 0.777072
JPY 161.061946
KES 141.88023
KGS 95.094156
KHR 4380.964858
KMF 492.004547
KPW 986.354973
KRW 1601.071317
KWD 0.338069
KYD 0.898682
KZT 557.183496
LAK 23688.554446
LBP 98650.025174
LKR 323.77412
LRD 219.055278
LSL 20.939938
LTL 3.236056
LVL 0.66293
LYD 5.297694
MAD 10.461464
MDL 19.256918
MGA 5097.248275
MKD 61.454645
MMK 2300.773509
MNT 3844.69323
MOP 8.776202
MRU 43.723365
MUR 48.849695
MVR 16.936109
MWK 1899.729173
MXN 22.386696
MYR 4.862473
MZN 69.669087
NAD 20.939938
NGN 1676.486674
NIO 40.164587
NOK 11.790932
NPR 150.016552
NZD 1.95777
OMR 0.421939
PAB 1.09595
PEN 4.030922
PGK 4.49162
PHP 62.914741
PKR 307.248605
PLN 4.267959
PYG 8823.836132
QAR 3.989667
RON 4.979528
RSD 117.168119
RUB 92.50772
RWF 1545.789905
SAR 4.110221
SBD 9.315355
SCR 16.229719
SDG 656.680085
SEK 10.947921
SGD 1.475122
SHP 0.861245
SLE 24.933268
SLL 22981.523891
SOS 624.183586
SRD 40.007558
STD 22683.951476
SVC 9.589967
SYP 14249.362274
SZL 20.939938
THB 37.609069
TJS 11.886343
TMT 3.832987
TND 3.349906
TOP 2.635115
TRY 41.641737
TTD 7.3774
TWD 36.393908
TZS 2920.947824
UAH 45.443935
UGX 4007.42983
USD 1.09595
UYU 46.305552
UZS 14175.789661
VES 77.401047
VND 28259.561187
VUV 133.834687
WST 3.068195
XAF 656.006063
XAG 0.037037
XAU 0.000361
XCD 2.959209
XDR 0.818399
XOF 656.006063
XPF 119.331742
YER 269.102584
ZAR 20.929909
ZMK 9864.868719
ZMW 30.585111
ZWL 352.89544
  • RELX

    -3.2800

    48.16

    -6.81%

  • BCC

    0.8100

    95.44

    +0.85%

  • BCE

    0.0500

    22.71

    +0.22%

  • GSK

    -2.4800

    36.53

    -6.79%

  • RYCEF

    -1.5500

    8.25

    -18.79%

  • SCS

    -0.0600

    10.68

    -0.56%

  • RIO

    -3.7600

    54.67

    -6.88%

  • JRI

    -0.8600

    11.96

    -7.19%

  • RBGPF

    69.0200

    69.02

    +100%

  • NGG

    -3.4600

    65.93

    -5.25%

  • CMSC

    0.0300

    22.29

    +0.13%

  • VOD

    -0.8700

    8.5

    -10.24%

  • AZN

    -5.4600

    68.46

    -7.98%

  • BTI

    -2.0600

    39.86

    -5.17%

  • CMSD

    0.1600

    22.83

    +0.7%

  • BP

    -2.9600

    28.38

    -10.43%

Asia-Pacific gets new weapon in fight against drug-resistant TB
Asia-Pacific gets new weapon in fight against drug-resistant TB / Photo: Nhac NGUYEN - AFP

Asia-Pacific gets new weapon in fight against drug-resistant TB

A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.

Text size:

The region had most of the world's estimated 10.6 million new TB cases in 2022, and more than half of the 1.3 million deaths, World Health Organization (WHO) figures show.

While TB can be successfully treated with antibiotics, more than three percent of new TB patients are resistant to commonly prescribed drugs.

Until recently, treatment for these patients involved daily painful injections or a fistful of pills for 18 months or longer, while some endured severe side effects such as nausea and, in extreme cases, blindness.

Many people prematurely quit their treatment, which had a success rate of 63 percent or lower.

Now, a new drug regimen involving fewer pills and side effects is being rolled out in the Asia-Pacific, including the Philippines, Vietnam and Indonesia, where trials have shown a more than 90 percent cure rate after six months.

The treatment, known as BPaL, combines the antibiotics bedaquiline, pretomanid and linezolid, and has received regulatory approval in more than 60 countries since 2019, according to the non-profit TB Alliance, which developed it.

The WHO updated its guidelines in 2022 to allow BPaL to be used with or without a fourth antibiotic called moxifloxacin.

BPaL has been life-changing for Filipino cook Efifanio Brillante, who was diagnosed with drug-resistant TB in June 2022 and initially went on an older form of treatment.

Brillante, 57, was swallowing 20 tablets a day, but it left him feeling so nauseous that he couldn't work or eat.

He stopped the medication after two weeks even though he knew the decision could be fatal.

"It's very difficult. You're always in bed," Brillante told AFP about his experience of having TB.

"Sometimes I couldn't even breathe."

The following month, Brillante joined a BPaL trial at the Jose B Lingad Memorial General Hospital in Pampanga province, north of the Philippine capital Manila.

He took between three and seven pills a day and was cured after six months.

"I'm very thankful that I was healed," Brillante told AFP in his home.

"If I didn't take that BPaL, I might already be buried in the cemetery."

- 'A curable disease' -

TB, once called consumption, is caused by a bacteria that primarily attacks the lungs and is transmitted through the air by infected people, for example by coughing.

While it is found in every country, poorer people living and working in overcrowded conditions are at higher risk of the disease.

Eight countries accounted for two-thirds of new TB cases in 2022: India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and the Democratic Republic of Congo.

One of the biggest challenges of treating drug-resistant TB has been getting patients to take the full course of their medication.

Even in countries where treatment is free, patients face crippling travel costs to hospitals and loss of income, or even their job, due to the illness and side-effects of the drugs, leading many to stop taking their pills.

In Vietnam, most people diagnosed with TB are from low-income families, Hoang Thi Thanh Thuy from the Vietnam National Tuberculosis Program told AFP.

Nearly everyone with drug-resistant TB endured "catastrophic" expenses over the period of their treatment, she said.

"All of these difficulties can affect patient compliance and lead to poor treatment and increasing drug resistance," Thuy said.

Identifying people with TB is also a challenge.

In Indonesia, some healthcare facilities are still not able to properly diagnose the disease, said Imran Pambudi of the health ministry.

Fear of social stigma from a positive diagnosis is also common.

"We're trying to educate them that TB is a curable disease," said Irene Flores, who led the BPaL trial at the Jose B Lingad Memorial General Hospital in the Philippines.

"If they come early, we can prevent complications."

- More investment needed -

After years of decline, the number of people falling ill with TB and drug-resistant tuberculosis began increasing during the Covid-19 pandemic, which disrupted diagnosis and treatment, the WHO said previously.

After gargantuan global efforts to develop a vaccine against the coronavirus, the WHO has called for increased funding to fight TB.

"As TB stopped being a high income-country problem, motivation to invest in research and development for new TB drugs dried up," said Sandeep Juneja, senior vice president of market access at the TB Alliance.

To help accelerate the rollout of BPaL, with or without moxifloxacin, the TB Alliance has set up a "knowledge hub" in Manila to provide training and assistance to other countries.

In India, where BPaL has been approved, there is growing impatience for it to be introduced into health clinics given the country's world-beating caseload.

"BPaL should be rolled out soon because it will spare patients a lot of headaches and provide psychological relief too, besides reducing cost of treatment in the long run," said Ravikant Singh, founder of advocacy group Doctors For You.

Juneja said the new regimen meant treating drug-resistant TB was no longer a guessing game of whether a patient would survive or not.

But more is needed to be done, he added.

"I hope this is... just the beginning of a new era of TB treatment where they will be even simpler, even shorter."

burs-pam/amj/dhw/jfx

T.L.Marti--NZN